title: Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?
abstract: BACKGROUND
  Amyloid A (AA) amyloidosis can complicate chronic inflammatory diseases, chronic infections and recurrent periodic fever syndromes. Its treatment is challenging, given its heterogeneous spectrum of etiologies.
  
  
  OBJECTIVE
  To review the available literature regarding treatment options for AA amyloidosis, particularly focusing on eprodisate, a newly developed inhibitor of fibrillogenesis.
  
  
  METHODS
  A PubMed search was performed without any date limits, mainly using the search terms 'amyloidosis', 'colchicine', 'eprodisate', '1,3-propanedisulfonate', 'NC-503', 'Fibrillex' and 'TNF-blockers'.
  
  
  CONCLUSIONS
  Antibiotics and colchicine are effective in preventing and treating infection-related and familial Mediterranean fever-related AA amyloidosis, respectively. Recently, TNF-alpha blockers have emerged as effective agents in inflammatory AA amyloidosis. Eprodisate binds to the glycosaminoglycan binding site on amyloid fibrils, thus targeting amyloid fibril polymerization and tissue deposition. Eprodisate has possible applicability to other types of amyloidosis; the results of a recent randomized trial showed that it may slow the progression of AA amyloidosis-related renal disease but confirmatory studies are necessary.
authors.affiliation: Arcispedale Santa Maria Nuova, Nephrology Department, V. le Risorgimento 80, Reggio Emilia, Italy lmanenti@hotmail.com
authors.forename: Lucio
authors.initials: L
authors.lastname: Manenti
authors.forename: Pius
authors.initials: P
authors.lastname: Tansinda
authors.forename: Augusto
authors.initials: A
authors.lastname: Vaglio
mesh_terms: D000686:Amyloidosis / Q000188:drug therapy*; D003078:Colchicine / Q000627:therapeutic use; D006025:Glycosaminoglycans / Q000037:antagonists & inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011407:Propane / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000685:Serum Amyloid A Protein / Q000378:metabolism; D013451:Sulfonic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D006025:Glycosaminoglycans; D007166:Immunosuppressive Agents; D000685:Serum Amyloid A Protein; D013451:Sulfonic Acids; D014409:Tumor Necrosis Factor-alpha; C520274:eprodisate; D003078:Colchicine; D011407:Propane